Working… Menu

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00651144
Recruitment Status : Completed
First Posted : April 2, 2008
Last Update Posted : April 16, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to obtain data of the coadministration of ezetimibe and rosuvastatin to support the concomitant use of these two drugs in patients requiring additional cholesterol-lowering management. Treatment is administered for 14 days.

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Atherosclerosis Drug: Ezetimibe + Rosuvastatin Drug: Rosuvastatin Drug: Placebo Drug: Ezetimibe Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: SCH 058235: Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Rosuvastatin in Healthy Hypercholesterolemic Subjects
Study Start Date : March 2003
Actual Primary Completion Date : May 2003
Actual Study Completion Date : May 2003

Arm Intervention/treatment
Experimental: Ezetimibe + Rosuvastatin Drug: Ezetimibe + Rosuvastatin
oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
Other Names:
  • Zetia
  • SCH 58235
  • Crestor

Active Comparator: Ezetimibe Drug: Ezetimibe
oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
Other Names:
  • Zetia
  • SCH 58235

Active Comparator: Rosuvastatin Drug: Rosuvastatin
oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
Other Name: Crestor

Placebo Comparator: Placebo Drug: Placebo
oral tablets; two ezetimibe placebo once daily for 14 days

Primary Outcome Measures :
  1. Percent change from baseline in total cholesterol, LDL-C, HDL-C, and triglycerides. [ Time Frame: Day 15 ]
  2. Safety: adverse events, laboratory test results, physical examination, vital signs. [ Time Frame: Throughout study ]

Secondary Outcome Measures :
  1. Evaluate potential for PK interaction between ezetimibe and rosuvastatin as indicated by Cmax and AUC. [ Time Frame: Day 14 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females between the ages of 18 and 55 years inclusive, having a Body Mass Index (BMI) between 19-31 inclusive. BMI=weight (kg)/height (m^2).
  • Subjects must have untreated hypercholesterolemia with a directly measured fasting LDL-C >=130 mg/dL (3.37 mmol/L) at Screening and on Day -1. Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with the study evaluations.
  • Subjects must have a normal or clinically acceptable physical exam and ECG (12-lead recorded at 25 mm/s and reporting heart rate and PR, QRS, QT, and QTc intervals).
  • Subjects' clinical laboratory tests (CBC, blood chemistries, and urinalysis) must be within normal limits or clinically acceptable to the investigator/ sponsor.
  • Screen for drugs with high potential for abuse must be negative.
  • Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules.
  • Subjects must be willing to comply with the NCEP Step 1 diet for at least one week as outpatients, and during the inpatient treatment period.
  • Female subjects must be of nonchildbearing potential (ie, surgically sterilized or postmenopausal for at least one year), or, if they are of childbearing potential they must be using a medically accepted method of birth control prior to Screening and agree to continue its use during the study or be surgically sterilized (eg, hysterectomy or tubal ligation). Females of childbearing potential should be counseled in the appropriate use of birth control while in this study. Females who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study.
  • Female subjects must have a negative serum pregnancy test (beta-hCG) at Screening.

Exclusion Criteria:

  • Female subjects who are pregnant, intend to become pregnant, or are nursing.
  • Subjects who previously received or were treated with ezetimibe (SCH 58235) or rosuvastatin.
  • Subjects who previously received or were treated with lipid lowering drugs (including OTC fish oil and phytosterols) within 6 weeks of Visit 1.
  • Any subject who does not comply with the requirement that he/she should not have used any prescription or over-the-counter drugs (except for aspirin or acetaminophen [paracetamol]) within two weeks prior to study drug administration nor alcohol within 48 hours prior to study drug administration.
  • Subjects who have used any investigational drugs or donated blood within 30 days of study entry.
  • Subjects with pre-existing gallbladder disease or a history of liver function test abnormalities.
  • Subjects who smoke more than ten cigarettes or equivalent tobacco use per day.
  • Subjects who have a clinically significant allergy or intolerance to foods or drugs, especially to any component of ezetimibe (ZETIA™/EZETROL™) or rosuvastatin (CRESTOR™).
  • Subjects who are positive for HIV antibodies, hepatitis B surface antigen or hepatitis C antibody.
  • Subjects with a history of mental instability or who have been or are being treated for mood disorders.
  • Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • Subjects who are participating in any other clinical study.
  • Subjects who are part of the staff personnel directly involved with this study.
  • Subjects who are a family member of the investigational study staff.
Publications of Results:
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00651144    
Other Study ID Numbers: P03317
First Posted: April 2, 2008    Key Record Dates
Last Update Posted: April 16, 2015
Last Verified: April 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors